News
Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.
According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...
A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.
Hosted on MSN8mon
What Is the Prognosis of Multiple Myeloma? - MSNIn multiple myeloma, the five-year relative survival rate—the proportion of people who live at least five years after the initial diagnosis—varies widely depending on the stage of the disease.
During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...
15d
MedPage Today on MSNWhat to Know About Treating Frail Elderly Patients With Multiple MyelomaMultiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients are older than 75, and 10% are older than 80. Along with this worldwide ...
2d
Medpage Today on MSNTrispecific Antibodies Emerging in Multiple MyelomaBuilding on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...
Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.
The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.
Send comments and news tips to news@medscape.net. Cite this: IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts Survival - Medscape - December 08, 2024.
Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...
Multiple myeloma is a type of blood cancer that happens in the bone marrow (the soft, spongy tissue inside the bones). Tecvayli attaches to a protein called BCMA that is found on the surface of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results